Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446874 | 0.84 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2MAPTPDGFRB | |
| SCHEMBL27836789 | 0.79 | MAPT (0.45) | KDM4ESMN1; SMN2MAPTPDGFRBPDGFRA | |
| SCHEMBL3661273 | 0.79 | KDM4E (0.48) | KDM4EALDH1A1SMN1; SMN2MAPTPDGFRB | |
| SCHEMBL30908162 | 0.76 | ALDH1A1 (0.50) | KDM4EALDH1A1SMN1; SMN2MAPTBACE1 | |
| SCHEMBL557993 | 0.76 | CSNK1D (0.47) | MAPTPDGFRBPDGFRACASP3SENP8 | |
| SCHEMBL332075 | 0.76 | MAPT (0.43) | KDM4EMAPTPDGFRBPDGFRACASP3 | |
| SCHEMBL30673769 | 0.76 | MAPT (0.43) | KDM4EMAPTPDGFRBPDGFRACASP3 | |
| SCHEMBL1633846 | 0.76 | BACE1 (0.47) | KDM4EALDH1A1SMN1; SMN2MAPTBACE1 | |
| SCHEMBL29516187 | 0.76 | BACE1 (0.47) | KDM4EALDH1A1SMN1; SMN2MAPTBACE1 | |
| SCHEMBL28049988 | 0.76 | ESR2 (0.46) | KDM4EALDH1A1SMN1; SMN2PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4329755-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-9493459-B2 | Azetidine and piperidine compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160176874-A1 | AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2016-06-23 | — | — | US | disclosed |
| US-9303028-B2 | Azetidine and piperidine compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150353508-A1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-9174992-B2 | Heterobicyclic compounds | AMGEN INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174992-B2 | Heterobicyclic compounds | AMGEN INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174992-B2 | Heterobicyclic compounds | AMGEN INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9139538-B2 | Quinolinyl glucagon receptor modulators | PFIZER INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2734503-B1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | PFIZER (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| EP-2024342-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | Pfizer Products Incorporated (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | KDM4E 2041/4885ALDH1A1 1098/4885SMN1; SMN2 2141/4885 |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | KDM4E 2041/4885ALDH1A1 1098/4885SMN1; SMN2 2141/4885 |
| US-20160176874-A1 | AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE9A, PDE2A | KDM4E 750/4885ALDH1A1 336/4885SMN1; SMN2 2366/4885 |
| US-20150353508-A1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | KDM4E 4299/4885ALDH1A1 3335/4885SMN1; SMN2 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.